GlassScriptPhysician profile
Dawn Y Lam
NPI 1720081029
$2,644.65
in general payments reported to CMS, 2019-2025
10 companies · $561 in 2025
The $561 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2023: $876 · 2024: $667 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,000 · Food and Beverage: $804 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,000.00 |
| Food and Beverage | $804.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $700.83 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Glaukos Corporation | $535.40 | 2023-2025 | Ce-Marked Kxla System, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Alcon Vision LLC | $441.48 | 2019-2025 | Air Optix |
| Johnson & Johnson Vision Care, INC. | $433.51 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $243.40 | 2023-2025 | Alden Scleral Zenlens, Alden Corneal Gp, Miebo |
| Genentech USA, INC. | $128.38 | 2023 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.17 | 2019 | |
| Sun Pharmaceutical Industries INC. | $40.26 | 2025 | |
| Dompe US, INC. | $29.22 | 2025 | Oxervate |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.